Birth Month Linked to Timing of Influenza Vaccination in Young Children
By Elana Gotkine HealthDay Reporter
THURSDAY, Feb. 22, 2024 -- For young children, birth month is associated with timing of influenza vaccination, according to a study published online Feb. 21 in The BMJ.
Christopher M. Worsham, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues examined optimal timing of influenza vaccination in young children in a population-based cohort study conducted among commercially insured children aged 2 to 5 years who were vaccinated against influenza during 2011 to 2018.
A total of 819,223 children aged 2 to 5 years received influenza vaccination during the study period. The researchers found that children who were vaccinated in November and December were the least likely to have an influenza diagnosis; the finding may have been confounded by unmeasured factors influencing vaccination timing and influenza risk. Vaccination often occurred on days of preventive care visits and during birth months; children born in October were disproportionately vaccinated during October and were vaccinated later and earlier than those born in August and December, respectively. The lowest rate of influenza diagnosis was seen for children born in October (e.g., 2.7 percent versus 3.0 percent for those born in August; adjusted odds ratio, 0.88).
"The findings support current recommendations that children be vaccinated in October preceding a typical influenza season," the authors write.
One author disclosed ties to pharmaceutical companies.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes
TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...
FDA Approves Capvaxive Pneumococcal 21-Valent Conjugate Vaccine
FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved the Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal...
No Evidence That Live Vaccines Are Unsafe for Patients on Dupilumab
FRIDAY, June 14, 2024 -- There is no evidence to suggest that administration of live vaccines to patients receiving dupilumab is unsafe, and vaccine efficacy is not affected by...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.